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The RIG-I-like receptors (RLRs) RIG-I, MDA5, and LGP2 play a major role in pathogen sensing of RNA virus
infection to initiate andmodulate antiviral immunity. The RLRs detect viral RNA ligands or processed self RNA
in the cytoplasm to trigger innate immunity and inflammation and to impart gene expression that serves to
control infection. Importantly, RLRs cooperate in signaling crosstalk networks with Toll-like receptors and
other factors to impart innate immunity and to modulate the adaptive immune response. RLR regulation
occurs at a variety of levels ranging from autoregulation to ligand and cofactor interactions and posttransla-
tional modifications. Abberant RLR signaling or dysregulation of RLR expression is now implicated in the
development of autoimmune diseases. Understanding the processes of RLR signaling and response will
provide insights to guide RLR-targeted therapeutics for antiviral and immune-modifying applications.RIG-I like receptors (RLRs) are a family of DExD/H box RNA
helicases that function as cytoplasmic sensors of pathogen-
associated molecular patterns (PAMPs) within viral RNA. The
RLRs signal downstream transcription factor activation to drive
type 1 interferon (IFN) production and antiviral gene expression
that elicits an intracellular immune response to control virus
infection. To date, three RLR members have been identified:
RIG-I (retinoic acid-inducible gene I), which is the founding
member and therefore best characterized of this family, MDA5
(melanoma differentiation associated factor 5), and LGP2 (labo-
ratory of genetics and physiology 2 and a homolog of mouse
D11lgp2).
The three RLRs are broadly expressed in most tissues where
they signal innate immune activation in a variety of cell types.
Although they play a prominent role in triggering innate defenses
within myeloid cells, epithelial cells, and cells of the central
nervous system, their actions are not essential for IFN produc-
tion in plasmacytoid dendritic cells despite their expression in
this cell type. RLR expression is typically maintained at low levels
in resting cells but is greatly increased with IFN exposure and
after virus infection (Kang et al., 2004; Yoneyama et al., 2004,
2005). Further, MDA5 expression was shown to be virus induc-
ible in cells lacking the IFN receptor, suggesting that RLR
expression can be driven by a direct virus-inducible signal (Yount
et al., 2007). The priming of cells with IFN or ectopic expression
of the RLRs dramatically sensitizes them for PAMP recognition
and immune signaling (Yoneyama et al., 2004, 2005; Sumpter
et al., 2005), suggesting that RLR function is in part regulated
by their respective expression. Consistent with this idea, plurip-
otent cells noted to have attenuated interferon response to cyto-
plasmic RNA PAMPs express little or no RLRs, thus rendering
them refractory to cytoplasmic PAMP detection and signaling
(Chen et al., 2010).
RIG-I and MDA5 detect a variety of viruses and signal the
production of IFN and induction of an antiviral response. They
share a number of structural similarities (Figure 1) including their
organization into three distinct domains: (1) an N-terminal region
consisting of tandem caspase activation and recruitment
domains (CARD), (2) a central DExD/H box RNA helicase domain
with the capacity to hydrolyze ATP and to bind and possibly680 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.unwind RNA, and (3) a C-terminal repressor domain (RD)
embedded within the C-terminal domain (CTD) that in the case
of RIG-I is involved in autoregulation (Yoneyama et al., 2004,
2005; Saito et al., 2007). Although similarly organized, LGP2
lacks the N-terminal CARDs and is currently thought to function
as a regulator of RIG-I and MDA5 signaling (Yoneyama et al.,
2005).
Pathogen Sensing by the RLRs
Members of the RLR family have been implicated in the recogni-
tion of a variety of viruses, and a list of these viruses is summa-
rized in Table 1. Various studies have shown that RIG-I confers
recognition of the hepaciviruses and members of the Paramyxo-
viridae, Rhabdoviridae, and Orthomyxoviridae virus genera,
whereas MDA5 is associated with the detection of members of
the Picornaviridae (Kato et al., 2006). Thus, mice lacking either
RIG-I or MDA5 become highly susceptible to RNA virus infection
(Kato et al., 2006; Venkataraman et al., 2007; Satoh et al., 2010).
In contrast, a subset of viruses including dengue virus, West Nile
virus, and reovirus present PAMPs that are recognized during
acute infection by both MDA5 and RIG-I (Fredericksen et al.,
2008; Loo et al., 2008). Moreover, MDA5 has recently been impli-
cated in the recognition of murine norovirus (McCartney et al.,
2008). Although LGP2 possesses the ability to bind RNA, it has
yet to be shown to be involved in the actual detection of viral
RNA during infection (Yoneyama et al., 2005).
RIG-I was initially characterized as a dsRNA-binding protein
that triggered IFN induction and virus signaling in response to
the synthetic dsRNA poly(I:C) (Yoneyama et al., 2004) and was
then identified as a major factor controlling cell permissiveness
for hepatitis C virus replication (Sumpter et al., 2005). Several
studies have since led to the characterization of molecular
features involved in the activation of RIG-I-dependent signaling
(further reviewed by Schlee and Hartmann, 2010). RIG-I prefer-
entially recognizes RNA sequencesmarkedwith 50 triphosphory-
lated (50ppp) ends, which serve in part to define a non-self RNA
PAMP (Hornung et al., 2006). Removal of the 50ppp completely
from a PAMP RNA abrogates signaling, whereas diphosphate
ormonophosphatemodifications of the 50ppp severely attenuate
signaling (Hornung et al., 2006; Kim et al., 2008). Studies based
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Figure 1. Structural Representation of the RLRs and Their Adaptor
IPS-1
Key structural domains involved in signaling are shown. The RLRs consist of
CARD (caspase activation and recruitment domain); ATPase containing DEAD
box helicase (DEAD helicase); and a C-terminal domain (CTD) that in RIG-I and
LGP2 but not MDA5 encodes a repressor domain (RD) involved in autor-
egulation. LGP2 lacks the N-terminal CARDs. IPS-1 consists of a homologous
CARD, a proline-rich region (Pro), and a transmembrane domain (TM) on its C
terminus.
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independent of length, at least one phosphate at the 50 end of
the RNA is required to trigger RIG-I-dependent signaling but
the 50ppp is required for full signaling potential by RIG-I
(Pichlmair et al., 2006). Next-generation sequencing of RNA
derived from RIG-I-bound RNA complexes isolated from
influenza virus-infected cells confirm that RIG-I associates pref-
erentially with short 50ppp-RNA sequence motifs along RNA
containing some dsRNA regions (Baum et al., 2010). Compar-
ison of RIG-I and MDA5 interaction with synthetic dsRNA
poly(I:C) suggests that whereas MDA5 preferentially recognizes
high-molecular-weight poly(I:C) fragments, RIG-I shows aprefer-
ence for shorter RNA fragments and can also bind to ssRNA
(Kato et al., 2008). Consistent with these observations, Marques
et al. (2006) reported that blunt-end dsRNA fragments as short
as 23 bp can trigger RIG-I-dependent signaling and that RIG-I
has a preference for recognizing blunt-ended dsRNA over those
with 50 or 30 overhangs. Moreover, because ssRNA predicted to
impose limited or no secondary structure but containing 50ppp
can also serve as a potent PAMP ligand of RIG-I, it is likely that
RIG-I can interact with various RNA substrates based on the
presence of a 50ppp marking the RNA as potential non-self
PAMP. However, it should be noted that a synthetic 50ppp-
ssRNA failed to drive RIG-I signal activation in the absence of
at least a short complementary sequence or polynucleotide
motifs (see below), suggesting that 50ppp alone could be insuffi-
cient as a determinant of non-self for RIG-I recognition, which
may require additional motifs marking an RNA as non-self
(Schlee et al., 2009).
RNA Ligand Specifications
A number of studies suggest that sequence composition of an
RNA ligand may contribute to the activation of RIG-I-dependent
signaling. Two in particular reported that RIG-I preferentially
signals IFN expression in response to polyuridine motifs that
contain interspersed C nucleotides (known as poly-U/UC; Saito
et al., 2008) as present in the genome of hepatitis C virus (HCV)
that was produced to include 50ppp (Saito et al., 2008; Uzri and
Gehrke, 2009). Of note is that HCV has a ssRNA genome that is
noncapped and includes a 50ppp. Deletion of the poly-U/UC
motif from the HCV genome completely abrogated RIG-I-
dependent signaling despite the presence of a 50ppp within thegenome RNA, indicating that 50ppp is not sufficient to confer
RIG-I signaling induction but that additional PAMP motifs are
likely to work in concert with 50ppp to mark an RNA as a RIG-I
ligand. In support of this, further analyses revealed that polyuri-
dine-rich RNA motifs serve to enhance RLR signaling to ssRNA
PAMPs representing Ebola virus, influenza virus, and other
RNA viruses (Saito et al., 2008). In the second study, Gondai
et al. (2008) showed that extension of in vitro transcribed short
hairpin RNAs by one G abolished IFN induction by RIG-I.
However, because the addition of the G results in the formation
of overhangs that are inhibitory to RIG-I signaling, it is difficult to
differentiate whether signaling was abolished because of
sequence composition or because of the removal of blunt
ends. Overall, these studies serve to indicate that PAMP RNA
ligand composition, along with 50ppp, are important determi-
nants of a non-self signature for RIG-I recognition. Thus, 50ppp
along with the secondary motifs such as polyuridine runs as
well as specific short dsRNA structures may serve together to
mark a viral RNA as non-self for recognition by RIG-I. In support
of this notion, RIG-I has been reported to signal IFN induction in
response to 50ppp AU-RNA polymers that are generated by RNA
polymerase III (pol III) transcription with exogenous dAdTDNA as
templates (Ablasser et al., 2009; Chiu et al., 2009). In thismanner,
RIG-I is predicted to be able to respond to dsDNA from intracel-
lular pathogens (Kumar et al., 2006; Ablasser et al., 2009;
Monroe et al., 2009) through recognition of a non-self product
of pol III transcription. Furthermore, RNA cleavage products
generated by the 20,50-linked oligoadenylate-activated RNase L
ribonuclease can trigger RIG-I- and MDA5-dependent IFN
induction, and this may serve as a means to amplify the antiviral
response through production of RLR substrates (Malathi et al.,
2007, 2010). Of note, however, is that such RNase L cleavage
products do not contain a 50ppp but instead contain a 30 mono-
phosphate in a context of a short (<200 nt) length essential for
RLR signaling (Malathi et al., 2010). MDA5 further cooperates
with RNase L to signal IFN induction in response to a viral
mRNA from parainfluenza 5 virus (Luthra et al., 2011). Based
on the nature of RNase L cleavage products, these observations
suggest that RIG-I and MDA5 can signal IFN induction through
their recognition of small RNA products marked with specific
cleavage or processing signatures independently of 50ppp.
However, the exact nature of the PAMP motifs recognized by
the RLRs in this situation is not defined.
Based on recent studies, RIG-I ligand RNAmotifs that serve as
a PAMP in pathogen recognition can be described chiefly as a
50pppRNA encoding shortmotifs of PAMP recognition, including
dsRNA structure, ssRNA encoding polynucleotide runs of
specific length, and variable end arrangements of blunt or over-
hang that imparts stable binding toRIG-I.Moreover, RNAmarked
via endonucleolytic cleavage may offer PAMP signature through
combination of length and 50 or 30 terminal structure. Binding of
50pppRNA toRIG-I has been confirmed by crystal structure anal-
ysis of the RIG-I RD, also called the C-terminal domain or CTD.
In this case, the 50ppp terminus of the ligand RNA is predicted
to bind to RIG-I and anchor the RNA ligand through interaction
with specific charged residues within a ligand binding groove of
the RD or CTD (Cui et al., 2008; Takahasi et al., 2009; Lu et al.,
2010). In contrast, synthetic dsRNA poly(I:C) is predicted to
differentially bind to RIG-I via a dsRNA-interaction site withinImmunity 34, May 27, 2011 ª2011 Elsevier Inc. 681
Table 1. RLR Detection of Viral Genera and Viral RNA Genome
Type
Viruses Detected by RIG-I
Paramyxoviridae () ssRNA, NS
Sendai virus Kato et al., 2005;
Yoneyama et al., 2005
Newcastle disease virus Kato et al., 2005
respiratory syncytial virus Loo et al., 2008
measles Plumet et al., 2007
Nipah Habjan et al., 2008
human parainfluenza 5 mRNA Luthra et al., 2011
Rhabdoviridae () ssRNA, NS
vesicular stomatitis virus Kato et al., 2005;
Yoneyama et al., 2005
rabies virus Hornung et al., 2006
Orthomyxoviridae () ssRNA NS
influenza A Kato et al., 2006
influenza B Loo et al., 2008
Filoviridae () ssRNA NS
Ebola Habjan et al., 2008
Arenaviridae () ssRNA S
Lassa Habjan et al., 2008
lymphocytic choriomeningitis virus Zhou et al., 2010
Bunyaviridae () ssRNA S
Rift Valley fever virus Habjan et al., 2008
Flaviviridae (+) ssRNA NS
hepatitis C virus Sumpter et al., 2005;
Saito et al., 2007
Coronaviridae (+) ssRNA NS
murine hepatitis virus Roth-Cross et al.,
2008
Caliciviridae (+) ssRNA NS
murine norovirus-1 McCartney et al., 2008
DNA viruses
Epstein-Barr virus EBER Samanta et al., 2006
myxoma virus Wang et al., 2008
Viruses Detected by MDA5
Picornaviridae (+) ssRNA NS
encephalomyocarditis virus Gitlin et al., 2006;
Kato et al., 2006
Theiler’s virus Kato et al., 2006
Mengo virus Kato et al., 2006
DNA viruses
vaccinia virus Pichlmair et al., 2009
Flaviviruses Detected by Both MDA5 and RIG-I
Flaviviridae
Japanese encephalitis virus (Kato et al., 2006)
dengue virus (Loo et al., 2008)
West Nile virus (Fredericksen
et al., 2008)
Reoviridae dsRNA S
reovirus Kato et al., 2008;
Loo et al., 2008
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from all three RLRs suggest that they form distinct RNA-binding
loops that impart the basis for ligand specificity (Takahasi et al.,
2009). Although MDA5 encodes a RD-like motif analogous to
the RIG-I RD, this domain, referred to as the CTD, does not
impose autoregulation of MDA5 signaling as it does for RIG-I
(Saito et al., 2008). However, crystal structure reveals that the
MDA5 CTD assumes a highly structured fold similar to that of
the RIG-I and the LGP2 RD (Li et al., 2009a). NMR titration with
dsRNA showed that MDA5 interaction with dsRNA occurs
through electrostatic associations on a positively charged
surface. Moreover, these analyses predict that the MDA5 CTD
binds preferentially to dsRNA with blunt ends and not to dsRNA
with 50 or 30 overhangs. Although little is known about the RNA
ligands for LGP2, crystal structure and NMR studies predict
that LGP2 is likely to interact with a varety of RNA species (Murali
et al., 2008; Pippig et al., 2009; Takahasi et al., 2009).
RLR Activation and Autoregulation
Themechanisms of RLR signaling control are best understood in
the case of RIG-I, with little known currently on how MDA5 and
LGP2 activity is regulated beyond RNA binding. Structure-func-
tion analyses of RIG-I demonstrate that its signaling activity is
tightly regulated by autoregulation mediated by intramolecular
interactions between the CARDs and the RD (Saito et al.,
2007). These observations indicate a model of RIG-I autoregula-
tion in which, in the absence of an RNA ligand, RIG-I is held in
a ‘‘closed’’ conformation where it is predicted that the CARDs
are sequestered from signaling interactions through intramolec-
ular association with the RD (Figure 2). Based on crystal
structures analyses, the 50ppp terminus of a dsRNA ligand is pre-
dicted to bind to aa 802–925 within the RD or CTD of RIG-I
through electrostatic interactions (Cui et al., 2008). Subsequent
conformational changes are predicted to release the CARDs
from RD repression. In this ‘‘open’’ conformation, RIG-I then
becomes signaling active wherein it probably multimerizes and
the CARDs within this RIG-I complex are now able to mediate
associations with its adaptor protein, IPS-1 (also known as
MAVS, VISA, or Cardif), to induce IFN production and the
expression of host defense genes (as reviewed in Scott, 2010).
Consistent with thismodel of RLR activation, RIG-I mutants lack-
ing the RD signal constitutively whereas those lacking the CARD
exhibit dominant-negative activity in response to virus and
dsRNA (Yoneyama et al., 2004, 2005). Biochemical and struc-
tural analyses confirm that the RD or CTD of RIG-I adopt
a different fold when bound to an agonist RNA as compared to
RIG-I alone or RIG-I bound to an antagonist RNA (Saito et al.,
2008; Ranjith-Kumar et al., 2009; Lu et al., 2010). Thus, RIG-I
signaling initiation is controlled in part through a combination
of RNA ligand-binding and conformation changes that alter
self-interactions, leading to signaling induction or suppression.
As noted above, MDA5 does not encode an RD that self-
governs its signaling actions. In fact, unlike RIG-I, whenAnnotations regarding the virus genome include the nucleotide composi-
tion, e.g., single-stranded (ssRNA) or double-stranded RNA (dsRNA);
positive (+) or negative (–) sense genomic orientation, and segmentation
(S) versus nonsegmentation (NS).
Figure 2. Model for RIG-I Signaling Activation and Its Regulation
In the resting state, RIG-I is held in a ‘‘closed’’ conformation by casein kinase II
phosphorylation and autoregulatory intramolecular interactions with the
C-terminal RD within the CTD holds the CARDs unavailable for signaling.
During virus infection, RD engagement of a 50ppp RNA PAMP containing other
nonself signature(s), concommitant with K63-linked ubiquitination of RIG-I by
TRIM25 and RING finger protein leading to RIG-I activation (Riplet, otherwise
known as REUL or RNF135), leads to conformational changes that release
the CARDs from autoregulation. The model shows RIG-I binding to 50ppp
RNA containing poly-U/UC motif such as the HCV RNA genome (Saito et al.,
2008; Uzri and Gehrke, 2009). RIG-I then assumes an ‘‘open’’ conformation
that allows for oligomerization and CARD-dependent interaction with IPS-1,
which activates signaling molecules at the IPS-1 signalosome. These
interactions trigger a signaling cascade that culminates in IFN produc-
tion and expression of proteins with direct antiviral or immune-modulating
activities to control infection. To prevent excessive activation of innate immune
responses, RIG-I signaling activity is inhibited by (1) phosphorylation events
Immunity
Reviewectopically expressed, wild-type MDA5 imparts constitutive
signaling without the need for an RNA ligand to stimulate its acti-
vation (Saito et al., 2007). These observations suggest that inter-
action of MDA5 with specific regulatory proteins might serve to
mediate its signaling control. In support of this idea, studies of
Lgp2-deficient mice reveal that fibroblasts and myeloid cells
from these animals have major defects in innate immune
signaling induced by MDA5-specific viral or p(I:C) agonists (Ven-
kataraman et al., 2007; Satoh et al., 2010). Moreover, these
animals exhibit attenuated responses to RIG-I-specific stimuli,
suggesting that LGP2 may function as a cofactor of RLR
signaling. These observations, however, are in contrast to
in vitro studies of LGP2 structure and function in which ectopic
expression of LGP2 was shown to negatively regulate RLR
signaling. Although biochemical studies reveal that RNA-binding
and ATP hydrolysis activities are not required by LGP2 for its
negative regulation of RLR signaling (Bamming and Horvath,
2009; Li et al., 2009b), cells that express an LGP2 mutant that
has lost its ATP hydrolyzing activity are similarly impaired in
signaling of IFN induction in response to RNA virus infection as
are cells lacking LGP2 (Satoh et al., 2010). LGP2 encodes a func-
tional RD that when expressed alone can impart suppression of
RIG-I signaling, suggesting that LGP2 control of RLR signaling
may be regulated through RD interactions with RIG-I and
possibly MDA5 (Saito et al., 2007). Thus, ATPase activity,
specific RD interactions, and probably RNA ligand binding may
impart LGP2 activity as a positive or negative regulator of RLR
signaling. Additional studies to assess the role of each, as well
as the impact of dynamic LGP2 expression levels, on RLR
signaling control are needed in order to assign a role for LGP2
in innate immune signaling regulation.
The RLR Signaling Pathway: Effector Actions
and Regulation
As noted above, RIG-I and MDA5 signal IFN production in
response to virus infection through a common adaptor, IPS-1
(as reviewed in Scott, 2010). IPS-1 is a membrane-bound,
CARD-containing protein that is essential for RLR-dependent
IFN production in response to virus infection. Signaling is initi-
ated by the detection of viral RNA PAMPs, which induces RLR
activation and association with IPS-1 through homotypic
CARD-CARD interactions. In addition to the N-terminal CARD
which shares homology with the first CARDs of RIG-I and
MDA5, sequence analysis revealed a transmembrane domain
on the IPS-1 C terminus that anchors it to intracellular mem-
branes. Reports have placed IPS-1 on the outer membranes of
the mitochondria, the membranes of peroxisomes, and mito-
chondria-associated membranes (Scott, 2010; Dixit et al.,
2010; unpublished observations). RIG-I and MDA5 interaction
with IPS-1 serves to relocate the RLRs to IPS-1-associated
membranes where they and downstream signaling molecules
accumulate to form an IPS-1 signalosome that drives IFN
production (Hiscott et al., 2006; Lin et al., 2006a; Ohman et al.,that inhibit the K63-linked ubiquitination required for signaling activation, (2)
negative regulators that sequester PAMP from RIG-I, (3) association with
negative regulators or molecules that disrupt/destabilize its interaction with
IPS-1, and (4) K43-linked ubiquitination by RNF125, which targets RIG-I for
proteasomal degradation.
Immunity 34, May 27, 2011 ª2011 Elsevier Inc. 683
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Review2009; Dixit et al., 2010; unpublished observations). Signal trans-
duction culminates in the activation of a transcription program
leading to IFN production and the induction of the antiviral state.
Cell-Intrinsic Innate Immunity and IFN Actions
Key transcription factors involved in RLR signaling and the IPS-1
signalosome include interferon regulatory factor 3 (IRF3), IRF7,
and NF-kB (Paz et al., 2006). IRF3 and IRF7 are latent transcrip-
tion factors that upon signal transduction are phosphorylated by
the noncanonical IkB kinases IKK3 or TBK1. Phosphorylated
IRF3 and IRF7 form homo- and heterodimers that accumulate
in the nuclei where they bind to target sequences to drive gene
transcription. In contrast, NF-kB activation requires the IKK
complex-mediated phosphorylation of its inhibitory subunit
IkBa that is then subjected to ubiquitin-dependent degradation
by proteasomes. Activated IRF3 and/or IRF7 and NF-kB
together with the transcription complex of ATF-2 and c-Jun
and the transcription enhancer CBP-p300 assemble as part of
an enhanceosome to direct IFN-b transcription (Panne, 2008).
In most cell types except for plasmacytoid dendritic cells, IRF3
is constitutively expressed whereas IRF7 expression remains
low until it is induced in the presence of IFN in a positive feed-
back loop (Marie´ et al., 1998; Sato et al., 1998). IRF3 is therefore
thought to function in the immediate early enhanceosomes in
most cell types whereas IRF7 direct later transcription programs.
IRF3 and components of the NF-kB activation program have
been identified as constituents of an IPS-1 signalosome in
various studies (Hiscott et al., 2006; Lin et al., 2006a; Ohman
et al., 2009; Dixit et al., 2010; unpublished observations).
IFN-b that is produced and secreted as a result of the RLR
cascade binds to the IFN receptor in an autocrine or paracrine
manner to direct JAK-STAT signaling and the ISGF3-dependent
expression of interferon-stimulated genes (ISGs). This signaling
serves to amplify the IFN response by increasing the expression
of IFN-a subtypes in a positive feedback loop. Other ISGs
include those encoding proteins with direct antiviral activity
such as viperin (Cig5), the ISG56 or IFIT family of proteins,
OAS, and Mx-1; immune-proteasome components involved in
antigen presentation; PAMP receptors including all three RLRs
and members of the Toll-like receptor (TLR) family; transcription
factors such as IRF-7; as well as numerous proinflammatory
cytokines and chemokines (Loo et al., 2008; Poeck et al.,
2010). The end result of ISG expression is the induction of cellular
conditions and immune regulation that cooperate to control
infection and the establishment of an antiviral state.
Inflammatory Signaling
In addition to inducing the expression and production of IFN and
ISGproducts, virus infection and signaling through the RLRs also
induces the expression of the IFN-l family of IL-10-related cyto-
kines known collectively as type III interferon (IFN-l) (as reviewed
in Donnelly and Kotenko, 2010) and various proinflammatory
cytokines to control infection (Poeck et al., 2010). Onoguchi
et al. (2007) showed that RLR signaling through RIG-I, IPS-1,
TBK1, and IRF-3 are required for the induction of IFN-l after
Newcastle disease virus (a paramyxovirus) infection, and anal-
yses of the promoter regions upstream in IFN-l genes reveal
numerous cis-acting elements for IRFs and NF-kB binding
(Osterlund et al., 2005; Onoguchi et al., 2007). Taken together,
the data strongly suggest that type I IFN and IFN-l induction
both occur through similar pathways and that RLR signaling684 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.also induces the expression of IFN-l to control virus infection.
In terms of the proinflammatory response, recent studies
suggest that RLR signaling mediates this response via two
pathways (Poeck et al., 2010). The first involves IPS-1-CARD9-
Bcl10-dependent transcription of proinflammatory genes,
many of which are NF-kB target genes. The second involves
RIG-I association with ASC protein to trigger caspase-1-depen-
dent inflammasome activation and the processing of proinflam-
matory cytokines such as IL-1b and IL-18 into their mature
forms. Thus, RLR signalingmay drive bifurcation beyond or inde-
pendently of IPS-1 to mediate the inflammatory response that
accompanies interferon production and adaptive immunity.
Signaling Cross Talk
RLR signaling shares a number of components in common with
other cellular pathways involved in immune protection. RLR
signaling to IRF3, IRF7, and NF-kB is regulated by complex
signaling transduction events that involve components previ-
ously associated with the tumor necrosis factor receptor I
(TNFRI) and TLR signaling pathways. IPS-1 interacts with the
TNFR-associated death domain (TRADD) protein, and its recruit-
ment is important for RLR signaling (Michallet et al., 2008).
TRADD exists in a complex with Fas-associated death
domain-containing protein (FADD) and the death domain kinase
RIP1. Signaling through the IPS-1-associated TRADD-FADD-
RIP1 complex results in the recruitment of TANK and NEMO to
the IPS-1 signalosome to facilitate IRF3 and IRF7 activation by
TBK1, IKKa-IKKb-dependent activation of NF-kB, and IFN
production (Kawai and Akira, 2009). In addition, TBK1 and IKK3
associate with the adaptor proteins NAP1 and SINTBAD (Sasai
et al., 2006; Ryzhakov andRandow, 2007). Although the relation-
ship between thesemolecules is unclear, knockdown of NAP1 or
SINTBAD impaired virus-induced signaling through both the TLR
and RLR pathways. A recent discovery of novel human IKK3
splice variants shows that the splice variants vary in their ability
to interact with TANK, NAP1, and SINTBAD, and this may serve
as a basis for directing the different signaling functions of IKK3
within the RLR signaling program (Koop et al., 2011).
The RLR signaling program further intersects with the inflam-
masome signaling pathway. Moore et al. (2008) has identified
NLRX1 (Nod9), a member of the nucleotide-binding domain
and leucine-rich-repeat-containing (NLR) family, in the regulation
of RLR signaling. NLRX1 localizes to the outer membrane of the
mitochondria, and its interactions with IPS-1 potently inhibits
RLR-dependent IFN induction by disrupting IPS-1 interactions
with signaling-active RLRs. Depletion of NLRX1 expression
enhanced virus-induced signaling and decreased virus replica-
tion, confirming NLRX1 as a negative regulator of RLR-induced
antiviral responses. In contrast, NLRC5, another member of
the NOD-like protein family, interacts with RIG-I and MDA5 but
not IPS-1 to inhibit RLR-mediated IFN responses (Cui et al.,
2010). NLRC5 interaction with IKKa and IKKb further blocked
their phosphorylation and inhibited their NF-kB activating activ-
ities. Consistent with this finding, siRNA silencing of NLRC5
expression was able to enhance NF-kB transcriptional activity
to drive IFN production and signaling of the antiviral response.
Other studies have revealed membrane-associated or mito-
chondria-interacting cofactors as RLR signaling regulators,
including mitofusin 1 and 2 (Yasukawa et al., 2009; Castanier
et al., 2010; Onoguchi et al., 2010; Koshiba et al., 2011), various
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et al., 2010), and specific transmembrane proteins such as
STING (otherwise known as MITA or MPYS) (Ishikawa and
Barber, 2008; Zhong et al., 2008). In the case of the mitofusins,
they are thought to link endoplasmic reticulumwithmitochondria
to govern mitochondria dynamics that occur during virus
infection, probably influencing IPS-1-dependent RLR signaling
(Yasukawa et al., 2009; Castanier et al., 2010; Onoguchi et al.,
2010; Koshiba et al., 2011). STING has been identified as an
RLR signaling cofactor and essential signaling adaptor protein
that directs innate immune responses to DNA viruses (Ishikawa
and Barber, 2008; Zhong et al., 2008). Thus, its role in RLR
signaling in RNA virus infection may offer overlap with the host
response to DNA virus infection. These interactions of NLRs,
mitofusins, STING, and other mitochondrial proteins with the
RLR signaling pathway are likely to impose control of RLR
signaling events that serve to program the proinflammatory
response, though this idea has yet to be validated.
Positive and Negative Regulation through Differential
Ubiquitination and Polyubiquitin Binding
RLR signaling is tightly regulated by a number of mechanisms to
prevent aberrant interferon production that may otherwise lead
to immune toxicity (such as a ‘‘cytokine storm’’) or the develop-
ment of autoimmune disorders. Posttranslational modifications
such as ubiquitination or deubiquitination of key components
of the RLR signaling pathway appears to be a major point of
regulation. RING finger protein leading to RIG-I activation or Rip-
let, otherwise known as RNF135 or REUL, is an ubiquitin ligase
that interacts with RIG-I but not MDA5 (Gao et al., 2009; Oshiumi
et al., 2009). It is reported to mediate the conjugation of K63-
linked polyubiquitin chains to RIG-I within the CARD at aa
K154, 164, and 172 (Gao et al., 2009) as well as within the RD
(Oshiumi et al., 2010) and is essential for virus-induced IFN
signaling. Mice deficient in Riplet expression were defective in
IFN and cytokine production during RNA virus infection and as
a consequence were more susceptible to virus infection
compared to wild-type mice. TRIM25 also mediates K63-linked
polyubiquitination of RIG-I at aa K172 during virus infection.
This modification is thought to stabilize interactions between
RIG-I and IPS-1 to induce signaling activation and IFN produc-
tion (Gack et al., 2007, 2008). However, free K63-linked polyubi-
quitin chains are capable of inducing RIG-I activation in an in vitro
reconstitution of the RIG-I pathway, suggesting that it is K172-
mediated polyubiquitin binding and not ubiquitin modification
that might drive RIG-I activation (Zeng et al., 2010). The data
further suggest that K63-linked polyubiquitin chains act as
a second ligand to enhance RIG-I signaling activation. This
notion is also supported by the findings that (1) expression of
a K172R RIG-I mutant that cannot be polyubiquitinated was
able to reconstitute Sendai virus-induced signaling to wild-type
levels in RIG-I-deficient MEFs, and (2) the lysine 172 of RIG-I is
not conserved between different species (Shigemoto et al.,
2009). Nistal-Villa´n et al. (2010) recently reported the regulation
of TRIM25 activities through the phosphorylation of RIG-I at
specific residues. RIG-I phosphorylation at serine 8 and/or thre-
onine 170 inhibited TRIM25-RIG-I interaction and ubiquitination
of RIG-I. However, the regulation by phosphorylation of serine
8 is not likely to be universal because this aa residue is shared
only among primate RIG-I and is not conserved among nonpri-mate species. RIG-I signaling is also subject to regulation by
the ubiquitin-editing protein A20 (Lin et al., 2006b). A20 has
both deubiquitination and ubiquitin ligase activities. However,
structure-function analyses reveal that only the ubiquitin ligase
activity associated with its C terminus domain is important for
regulating RLR signaling. Overexpression of A20 selectively in-
hibited RIG-I-dependent activation of IRF3 and NF-kB whereas
its depletion from cells enhanced virus-induced signaling, sug-
gesting that it functions as a negative regulator in the RLR
pathway. In addition, TNFR-associated factor 3 (TRAF3), a
K63-linked E3 ubiquitin ligase that is essential for regulating
virus-induced IRF3 activation (Ha¨cker et al., 2006; Oganesyan
et al., 2006), was found to regulate IFN but not inflammatory
cytokine production during virus infection. TRAF3 binds to the
TRAF-interacting motif (TIM), which is found within the proline-
rich region of IPS-1 and facilitates IKK3 recruitment to the
IPS-1 signalosome. TRAF3 activity in RLR signaling is further
regulated by the E3 ubiquitin ligase Triad3A (Nakhaei et al.,
2009), the deubiquitinase OTUB1 and OTUB2 (Li et al., 2010),
the deubiquitinase DUBA (Kayagaki et al., 2007), and the inter-
feron-inducible gene FLN29 (Mashima et al., 2005; Sanada
et al., 2008), as well as by the stability of IKK3 interactions with
IPS-1 (Paz et al., 2009, 2011) and by interactions between the
Polo-like kinase 1 (PLK1) and IPS-1 (Vitour et al., 2009). Thus,
RLR signaling is regulated through multiple activities of ubiquiti-
nation ligase networks that operate alone or in concert. This
complexity of signaling control may serve to tune the RLR
response to specific stimuli.
RNF125 is another ubiquitin ligase that cooperates with the
ubiquitin E2 ligase HbcH5c to conjugate K48-linked ubiquitin
to RIG-I, MDA5, and IPS-1 to mediate proteasomal degradation.
RNF125 itself is an ISG whose expression is induced after virus
infection and its action is part of a negative feedback loop to
prevent excessive interferon production (Arimoto et al., 2007).
The activity of RNF125 is suppressed by UbcH8, the same ubiq-
uitin ligase that is responsible for conjugating ISG15 to target
proteins during virus infection (Arimoto et al., 2008). Based on
accumulating evidence, it is proposed that ISG15 interaction
with UbcH8 concurrent with virus-induced ISG15 expression
dissociates it from its interaction with RNF125. This action then
would facilitate RNF125 conjugation of ubiquitin to RIG-I and
other molecules to inhibit RLR signaling of IFN expression.
Consistent with this model, basal expression of RIG-I is higher
in Ube1-deficient cells that lack the ability to conjugate ISG15
as compared to wild-type cells, thus providing RIG-I amounts
that facilitate robust RLR signaling (Kim et al., 2008). In addition,
the tumor suppressor CYLD is a deubiquitinase that interacts
with both RIG-I and IPS-1. It was previously shown to be essen-
tial in preventing aberrant IKK3-and TBK1 activation (Zhang
et al., 2008). Consistent with this finding, cells deficient in
CYLD expression signal activation constitutively and exhibit a
hyperinduction of IFN during virus infection. Moreover, a recent
study suggests that CYLD functions to remove polyubiquitin
chains from RIG-I and TBK1 to inhibit IRF-3 signaling and RIG-I-
dependent IFN production from the IPS-1 signalosome (Fried-
man et al., 2008). These studies define a critical role for the
reversible ubiquitination of RLRs and cofactors within the RLR
signaling pathway in the regulation of RLR pathway signaling
during the immune response to virus infection.Immunity 34, May 27, 2011 ª2011 Elsevier Inc. 685
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Other Modifications, and Protein Interactions
The RLR signaling pathway is further regulated by additional
posttranslational modifications, including the phosphorylation,
acetylation, and SUMOylation of signaling components. Beyond
the modification events that govern ubiquitination described
previously, posttranslational modification of RIG-I may further
serve to prevent premature activation in the absence of PAMP
and represents another level of regulation of RLR activation.
For instance, casein kinase II phosphorylates RIG-I in its resting
state at aa residues threonine 770, serine 854, and serine 855
(Sun et al., 2011). Mutation of these sites, chemical inhibition,
or depletion of casein kinase II rendered RIG-I constitutively
active resulting in enhanced IFN induction. In contrast, the treat-
ment of cells with phosphatase inhibitor suppressed RLR-
dependent signaling, suggesting that phosphorylation of RIG-I
is required to maintain autoregulation by its RD. Additionally,
RIG-I was identified by mass spectrophotometry to be acety-
lated at amino acid residues K858 and K909; however, it remains
to be determined how lysine acetylation regulates RIG-I signal-
ing activity (Choudhary et al., 2009).
Downstream signaling components involved in RLR signaling
are also regulated by posttranslational modifications. Of note is
that virus-induced activation of TLR and RLR pathways is known
to lead to the SUMOylation of IRF3 and IRF7 at K152 and K406,
respectively. Mutants of these factors that do not support
SUMO modification exhibit enhanced IFN induction after viral
infection, suggesting that SUMO modification of IRF3 and IRF7
is a negative regulatory step in RLR signaling (Kubota et al.,
2008). Thus, specific modification of RLRs and their signaling
cofactors impose regulation of innate defense signaling at
a variety of levels ranging fromRLR activity to IPS-1 signalosome
assembly and function.
Interactions with regulatory proteins further serve as points of
control in RLR-dependent signaling. Primary to this is the inter-
action of RIG-I or MDA5 directly with IPS-1 to drive IPS-1 signal-
osome assembly and/or activation. Further, interaction of IPS-1
signalosome components with regulator factors serves tomodu-
late RLR signaling actions through IPS-1. For example, SIKE is
a physiological suppressor of TBK1 and IKK3 that keeps these
protein kinases sequestered as inactive complexes to prevent
unintended activation by either RLR (Huang et al., 2005). More-
over, the Atg5-Atg12 conjugate previously implicated in the
induction of autophagic responses directly associates with
RIG-I and IPS-1 CARDs to suppress virus-induced signaling
(Jounai et al., 2007; Takeshita et al., 2008). PSMA7 or the protea-
some a4 subunit associates with IPS-1 to inhibit virus-induced
RLR-mediated signaling, although it is unclear how this is
accomplished (Jia et al., 2009). Additionally, the tyrosine kinase
c-Src interacts with IPS-1, TBK1, and TRAF3, probably within
the IPS-1 signalosome, to enhance RLR-dependent IFN induc-
tion (Johnsen et al., 2009). Separately, the Src-like nonreceptor
protein kinase c-Abl has been shown to interact with and phos-
phorylate IPS-1 during virus infection to facilitate induction of
signaling to both IRF-3 and NF-kB (Song et al., 2010). Further-
more, Eyes absent 4 (EYA4) and its phosphothreonine-specific
phosphatase activity is required to facilitate RLR-mediated IFN
signaling (Okabe et al., 2009). EYA4 was reported to interact
with IPS-1, STING, and NLRX1, again most probably within the686 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.IPS-1 signalosome. Finally, dihydroxyacetone kinase (DAK)
selectively interacts with the MDA5 CARD to regulate MDA5-
mediated antiviral signaling, probably by altering the MDA5-
IPS-1 interaction (Diao et al., 2007). It is speculated that DAK
sequesters MDA5 in an inactive state but releases MDA5 from
such regulation during virus infection wherein it can bind to
and modulate the actions of IPS-1. Taken together, the studies
reviewed above demonstrate that the RLR pathway and the
activity of its components are subject to regulation through direct
protein interaction and/or posttranslational modifications that
act in concert to mediate RLR-induced IFN production and the
expression of immune-response genes to control virus infection.
RLRs Cooperate with Other PRRs in the Detection
of Viruses
During virus infection, RLRs do not operate alone to induce and
program antiviral immunity but are part of a concerted and cross-
talking antiviral program mediated by a variety of PRRs. An
example of how the RLRs and other PRRs interact to participate
in immune signaling during virus infection is well illustrated
through in vivo studies of West Nile virus (WNV) infection (a flavi-
virus) in mice. Genetic studies with knockout mice show that
a close cooperation between PRRs is important in triggering
the initial innate immune response and in defining the quality of
the adaptive immune response to limit WNV dissemination and
neuroinvasion. WNV infection of a mammalian host is initiated
by the bite of an infected mosquito and has been effectively
modeled in mice. The insect-to-mammal-host infection event
first transmits the virus to resident langerhans cells in the skin
and also probably skin fibroblasts. The infection stimulates local
IFN production and innate immune defenses through essential
RLR signaling within the infected cells and serves to suppress
peripheral spread of the virus. However, after an initial round of
replication at the skin portal of entry, the virus disseminates to
the draining lymph node, where it undergoes further amplifica-
tion in resident macrophages and DCs where it is engaged by
RLRs and TLRs to drive diversified IFN and proinflammatory
cytokine production, thus inducing a local inflammatory
response. Whereas RLR signaling is essential for sensing WNV
infection and for the initial triggering of the intracellular innate
immune response, the TLRs serve a secondary role in this
capacity to drive specific cytokine production leading to regula-
tion of the adaptive immune response and programming of cell-
mediated immunity (Daffis et al., 2009; Suthar et al., 2010). It
should be noted that the expression of TLRs and many of their
signaling cofactors is induced and enhanced by IFN (Hall and
Rosen, 2010). Thus, initial RLR signaling and IFN production
against virus infection serves to enhance TLR expression and
to potentiate the actions of the TLR signaling pathways. In this
capacity, the RLRs provide signaling crosstalk to enhance TLR
expression and function, leading to global immune modulation
that plays a role in controlling the peripheral dissemination of
WNV infection among tissues. At this point of the infection,
WNV is carried to the spleen via processes of infected cell migra-
tion and viremia, where the resident cells initiate RLR-dependent
innate immune actions after virus exposure. If WNV can over-
come or evade these antiviral actions, it will further replicate
and invade the central nervous system, resulting in encephalitis
and possibly death.
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tion. Although RIG-I-deficient cells are able to mount an IFN-
dependent antiviral response, this response is attenuated and
delayed in its onset compared to wild-type cells (Fredericksen
and Gale, 2006; Fredericksen et al., 2008). In contrast, antiviral
signaling is abrogated in cells lacking both RIG-I and MDA5 or
their common adaptor IPS-1. Correspondingly, the cells lacking
these factors support enhanced virus replication as compared to
wild-type cells, suggesting that RIG-I and MDA5 cooperate to
direct the innate immune response and the amplification of IFN
signaling to control WNV infection. Innate immune signaling
against other flaviviruses show a similar dependence on RIG-I
and MDA5 (Kato et al., 2006; Loo et al., 2008). This finding is
further supported by ex vivo studies showing that innate immune
signaling is abrogated in cells lacking IPS-1 but are RLR
signaling competent (Fredericksen et al., 2008; Daffis et al.,
2009; Suthar et al., 2010). Moreover, IPS-1-deficient mice exhibit
severe dysregulation of both innate and adaptive immune
processes that fail to contain the infection, resulting in neuroinva-
sion and increased susceptibility of mice toWNV infection (Daffis
et al., 2009; Suthar et al., 2010). Signaling crosstalk to the RLRs
from caspase 12-mediated pathways of the infected cells has
been shown to enhance TRIM25-mediated ubiquitination of
RIG-I, thus potentiating RLR signaling. Accordingly, caspase
12-deficient mice exhibit increased viral burden after WNV infec-
tion (Wang et al., 2010). These findings suggest that caspase 12
may provide signaling crosstalk that regulates RIG-I activity in
the control of virus infection.
Enhancement of TLR expression in response to RLR signaling
impacts MyD88-dependent signaling that controls cell type
susceptibility to WNV infection (Welte et al., 2009; Szretter
et al., 2010). Although there was little difference reported in the
systemic IFN response to WNV infection, MyD88-deficient
mice were shown to be more susceptible to WNV infection
than wild-type counterparts, and they exhibit increased periph-
eral spread of the virus with high viral load in the central nervous
system and reduced levels of leukocyte trafficking into the brain
(Szretter et al., 2010). These observations indicate that RLR
signaling crosstalk with MyD88-dependent TLR signaling
imparts control of WNV replication in neuronal cells.
RLRs crosstalk with TLRs to diversify the innate immune
response to virus infection, but this crosstalk can also have a
pathogenic outcome. Indeed, TLR3-deficient mice have been
shown to have improved survival rates to WNV infection as
compared to wild-type controls (Wang et al., 2004). The in-
creased survival was attributed to a decrease in the inflamma-
tory response that was mediating WNV penetration of the
blood-brain barrier. In this case, crosstalk of RLR signaling to
enhance TLR3 expression and pathway signaling was probably
a contributor to the pathogenic outcome. This idea is supported
by studies of mice lacking SARM, an adaptor protein that
negatively regulates TLR3. SARM-deficient mice exhibited
increased lethality after WNV challenge that was associated
with increased virus in the central nervous system, implicating
the RLR to TLR3 crosstalk and TLR3 function in the pathology
of WNV infection (Szretter et al., 2009). However, separate
studies indicate that TLR3 and its crosstalk with RLRs impart
protection from virus replication and WNV dissemination into
the central nervous system in both mice and humans (Konget al., 2008; Daffis et al., 2008). RLR signaling to enhance TLR7
expression may also serve to control WNV infection but through
immune cell modulation in which TLR7 imparts immune cell
homing to infected tissues (Town et al., 2009) and probably
in a cell-specific or context-dependent manner (Welte et al.,
2009). Thus, RLR signaling crosstalk to TLRs serves to enhance
TLR signaling programs for the regulation of innate immune
effector actions that control virus replication within infected cells
and that suppress virus spread and dissemination in vivo while
modulating immune cell trafficking and functions that suppress
infection in tissues.
RLR Regulation of the Adaptive Immune Response
In addition to its role in driving innate immune defenses, IFN
plays a major role in modulating the adaptive immune response.
IFN is required to promote T cell survival and clonal expansion
after antigen presentation (as reviewed in Mattei et al., 2010).
Moreover, interferon potently induces the cytolytic activity of
natural killer cells and cytotoxic lymphocytes (Biron et al.,
1999) and plays an important role in promoting B cell differenti-
ation and antibody production (Le Bon et al., 2001; Jego et al.,
2003). Interferon actions further facilitate antigen presentation
processes by promoting the expression of MHC class I mole-
cules on most cell types and costimulatory molecules on
antigen-presenting cells (Stark et al., 1998). However, the
specific role of RLR signaling in regulating interferon production
and its regulation of the adaptive immune response is less clear
and appears to vary from virus to virus.
Results showing that RLR signaling imposes modulation of
adaptive immunity are beginning to reveal how RLRs program
the immune response. As an example, mice that received an
influenza virus DNA-based vaccine coexpressing a RIG-I
agonist that activated RLR signaling exhibited increased virus-
specific serum antibody response as compared to those that
were provided with the DNA vaccine alone (Luke et al.,
2011). These results suggest that RLR signaling can enhance
antibody development driven by vaccine administration, but
they contrast somewhat to a study that compared TLR and
RLR signaling of adaptive immunity. In this case when infected
with influenza A virus, mice lacking MyD88 and thereby unable
to signal through most TLRs failed to induce antigen-specific
B and T cell activation, but by comparison mice lacking
IPS-1 and unable to mediate RLR signaling showed no such
defect (Koyama et al., 2007). However, and in contrast to this
study, mice lacking IPS-1 when infected with West Nile virus
(a flavivirus) exhibited elevated systemic IFN, proinflammatory
cytokine and chemokine levels, increased but dysregulated B
and T cell activation, loss of neutralizing antibodies despite
higher overall antibody production, and a general failure to
protect the mice from infection (Suthar et al., 2010). This study
also showed that T regulatory cells failed to expand during acute
infection of mice lacking IPS-1 that are therefore unable to signal
through RLR pathways. Moreover, Anz et al. (2010) further
observed that both T effector and T regulatory cells express
RIG-I and MDA5 and that RLR signaling is required for enceph-
alomyocarditis virus (a picornavirus)-induced regulation of T
regulatory cell function during infection. In a separate study,
IPS-1 was found to be essential for the innate immune but not
the cytotoxic T lymphocyte response in mice during respiratoryImmunity 34, May 27, 2011 ª2011 Elsevier Inc. 687
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results suggest that in the case of flavivirus and picornavirus
infections, RLR signaling is important in the control of the quality,
quantity, and balance of the adaptive immune response during
infection, whereas RLR regulation of the adaptive immune
response is likely to be specific and differential for specific virus
infections.
RLR Polymorphisms and Immune Disease
Accumulating evidence suggests that aberrant IFN induction
and the resulting signaling of innate immune programs is associ-
ated with autoimmune disease (reviewed by Hall and Rosen,
2010). Because they are receptors that regulate IFN induction,
there is increasing interest in assessing potential links between
RLR function and/or polymorphisms that may lead to differences
in susceptibility to infection and predispositions to autoimmune
diseases. Genetic screens have led to the identification of
a number of polymorphisms in IFIH1 (the MDA5 gene) that are
associated with resistance to type 1 diabetes (T1D), including
T946A, E627*, I923V, R843H, IVS8+1, and IVS14+1 (Smyth
et al., 2006; Concannon et al., 2008; Liu et al., 2009; Nejentsev
et al., 2009). The polymorphisms are associated with (1) reduced
IFIH1 transcription (Liu et al., 2009; Downes et al., 2010), (2)
disruption of conserved splice donor sites leading to the expres-
sion of nonfunctional MDA5 variants (Nejentsev et al., 2009),
and/or (3) expression of truncated or mutated variants of
MDA5 that lead to defective RNA-binding and/or IFN induction
(Shigemoto et al., 2009). It is also noted that accumulating
evidence reveals the presence of picornavirus RNA and viral
antigens in the pancreas, pancreatic islets, and PBMCs of T1D
patients as compared to healthy controls or patients with type
2 diabetes (as reviewed in Jaı¨dane et al., 2010). These studies
suggest that aberrant MDA5-mediated IFN induction during
picornavirus infection of pancreatic cells may underlie islet cell
damage and the onset of T1D. Consistent with this idea, mice
lacking one copy of MDA5 developed transient hyperglycemia
after infection with b cell-tropic encephalomyocarditis virus-D,
a b cell tropic virus (McCartney et al., 2011). Moreover, silencing
of MDA5 expression in rat pancreatic b cells by siRNA treatment
reduced poly(I:C) induced expression of proinflammatory cyto-
kine and IFN (Colli et al., 2010), suggesting that aberrant inter-
feron induction by MDA5 could be a factor in b cell programming
of T1D. In addition to its linkage with T1D, MDA5 was recently
identified as the 140 kDa autoantigenmost frequently associated
with clinical amyopathic dermatocyositis (Betteridge et al., 2009;
Sato et al., 2009; Nakashima et al., 2010). Subjects that exhibit
an accumulation of autoantibodies to MDA5 are often associ-
ated with a higher frequency of rapidly progressive interstitial
lung disease (Sato et al., 2005; Gono et al., 2010; Nakashima
et al., 2010).
The evidence implicating RIG-I involvement in autoimmune
disease is less clear. One report shows that subjects with
Crohn’s disease but not ulcerative colitis exhibit a selective
suppression of RIG-I expression in the intestinal epithelial
compartment (Funke et al., 2011). In another report, RIG-I-defi-
cient mice generated by the deletion of exons 4–8 spontaneously
develop a phenotype characteristic of autoimmune colitis. The
phenotype included inflammation and damage of the colon
mucosa, reduction in number and size of Peyer’s patches, and688 Immunity 34, May 27, 2011 ª2011 Elsevier Inc.suppression of Gai2 expression (Wang et al., 2007). Together,
these studies suggest a link between aberrant RIG-I expression
and autoimmune diseases involving the gut.
Polymorphisms leading to the expression of alternate RIG-I
variants have also been reported. One common, nonsynony-
mous polymorphism leads to the expression of a functional
RIG-I with an arginine to cysteine mutation at aa position 7
(Shigemoto et al., 2009) that is associated with increased anti-
viral signaling (Hu et al., 2010). This same polymorphism was
shown to be associated with a decrease in humoral immunity
development in children who were given the rubella vaccine
(Ovsyannikova et al., 2010). Peripheral blood mononuclear cells
(PBMCs) from patients who exhibit a second polymorphism
resulting in the expression of a nonfunctional variant of RIG-I
encoding a serine to isoleucine mutation at aa position 183
were severely attenuated in antiviral signaling against influenza
A virus and Sendai virus (Pothlichet et al., 2009). Furthermore,
a loss-of-function polymorphism of IPS-1 that led to the expres-
sion of a nonfunctional IPS-1 variant expected to abrogate RLR
signaling has been linked to a subtype of systemic lupus erythe-
matosus (Pothlichet et al., 2011). Taken together, the studies
suggest that dysregulation of RLR signaling programs may
lead to the development of autoimmune diseases, and poly-
morphisms in the RLR genes and their signaling components
may define susceptibility to virus infection.
Conclusion
RLRs are essential pathogen recognition receptors that impart
recognition of RNA virus infection. RLR signaling programs rely
on the IPS-1 adaptor protein and its assembly of a high-energy
signalosome that drives downstream activation of transcriptional
responses that induce interferon and antiviral and immune
modulatory genes that control virus replication and spread and
that serve to regulate the adaptive immune response. RLR
signaling activation by ligand interaction serves to initiate the
immune response to virus infection, so an increased under-
standing of the molecular features underlying these processes
could offer new strategies to consider for immune and antiviral
therapy by targeting the RLR pathway for the therapeutic control
of virus infection and enhancement of the immune response, and
strategies of immune suppression to control inflammation or
specific autoimmune diseases.
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